Cancer Network
Spotlight
CancerNetwork® Inaugural Face-OffContemporary Concepts in Hematologic OncologyReal-World Evidence in NSCLC Guides Clinical Decisions Register: Recent Advances in Multiple Myeloma: Insights from Experts at Dana Farber Cancer Institute and Massachusetts General Hospital
Clinical
View MoreAcute Myeloid LeukemiaBrain CancerBreast CancerColorectal CancerGastrointestinal CancerGenitourinary CancerGynecologic CancerHematologyLeukemiaLung CancerLymphomaPediatric CancersSkin Cancer
News
Clinical TopicsIntegrative CareGlobal BulletinAll NewsApproval Alert
Media
2 Minute DrillAround the PracticeBetween the LinesClinical ConsultExpert InterviewsFace OffMedical World NewsOncViewPodcastsReadout 360Year in Review
Conferences
Publications
All JournalsFor AuthorsTumor Board
CME/CE
Resources
Contemporary ConceptsInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsored
Subscribe
eNewsletterPrint Subscription

  • About
  • Advertise
  • CureToday.com
  • OncLive.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
  • MJHLS Brand Logo

© 2022 MJH Life Sciences and Cancer Network. All rights reserved.

CancerNetwork® Inaugural Face-Off

In a new series from CancerNetwork®, two teams of fellows from leading institutions go head-to-head to debate the latest datasets and advances in acute lymphoblastic leukemia.

EP. 1: Team Introductions: The Moffitt Marrowvingians vs The Memorial Sloan-Kettering Mavericks

May 6th 2022

Steven Frommeyer kicks off a new and exciting competitive series from CancerNetwork® and introduces the first 2 teams.

EP. 2: Use of Inotuzumab for ALL in the Frontline Setting

May 6th 2022

Nikesh Shah, MD, presents a trial published in Lancet Oncology in 2018 on the use of inotuzumab plus mini-CVD in the frontline setting for older patients with ALL.

EP. 3: HyperCVAD in Frontline ALL

May 13th 2022

Nikesh Shah, MD, explains a key trial evaluating the efficacy and toxicity of hyper-CVAD in acute lymphocytic leukemia (ALL).

EP. 4: Adoption of Pediatric-Inspired ALL Regimens by Adult Oncologists

May 13th 2022

Reem Akel, MD, presents a population-based study on the adoption of pediatric-inspired acute lymphoblastic leukemia (ALL) regimens by adult oncologists.